Undisclosed

all catalysts(0)

nothing on the calendar yet

News(10)

• Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease
  Eli Lilly has turned to one of its Gateway Labs residents to help the Big Pharma develop trans-amplifying RNA (taRNA) vaccines for infectious diseases.
  fiercebiotech · 13h ago
• Kolon TissueGene cuts 37 US staffers after Phase 3 fail
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
  This is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.
  biospace · 2d ago
• Slate, Fulcrum to combine in reverse merger
  Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.
  biopharma_dive · 3d ago
• J&J hands lymphoma bispecific CAR T back to AbelZeta
  Johnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront. The asset in June last year showed a 100% response rate as a second-line option in a Phase 1b study for 10 patients…
  biospace · 3d ago
• Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
  Antibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.
  fiercebiotech · 3d ago
• After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
  Two recent patient deaths—both involving severe immune reactions to high-dose, viral vector-delivered gene therapies and a lack of disclosure—have drawn international scrutiny to what appear to be…
  fiercebiotech · 6d ago
• Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
  The terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.
  biospace · 7d ago
• Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset
  Mereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.
  biospace · 8d ago
• Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
  Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.
  biopharma_dive · 9d ago